Robert W. Holloway, MD

Oncologists contemplate what ovarian cancer treatment will look like in the future and exciting clinical trials in progress.

Robert W. Holloway, MD, and Chad A. Hamilton, MD, provide clinical pearls for community physicians using maintenance therapies for ovarian cancer.

Key opinion leaders discuss how they decide between two regimens for ovarian cancer maintenance therapies.

Experts review the potential maintenance therapy approaches for a 64-year-old woman with stage IIIC high-grade serous ovarian cancer.

Dr. Chad Hamilton explains pivotal data from several important clinical trials in ovarian cancer.

Robert W. Holloway, MD, details how he decides to start maintenance therapy after first-line ovarian cancer treatments.

Chad A. Hamilton, MD, and Robert W. Holloway, MD, review the case of a 57-year-old woman with stage IIIA high-grade epithelial ovarian cancer.

Oncologists debate the need for genetic counseling for ovarian cancer patients and how to approach molecular testing alongside neoadjuvant chemotherapy.

Dr Robert W. Holloway explains his typical approach to ovarian cancer biomarker testing and sequencing.

Chad A. Hamilton, MD, and Robert W. Holloway, MD, discuss challenges clinicians face in treating ovarian cancer and review the current state of biomarker testing.